Hematology

Combination of immunotherapy and aspirin showed a substantial decrease in bowel and melanoma skin cancer growth in mice.

Treatment removes a tumor's defenses.

Chemotherapy drugs can convert gastrointestinal bacteria into toxic species that causes severe diarrhea.

Clinical outcomes expected to continue improving as new treatments arrive.

New approach may combine with existing medications to improve survival.

Ixazomib is the first investigational oral proteasome inhibitor for relapsed and/or refractory multiple myeloma.

Daratumumab monotherapy slows disease progression a year after treatment.

Researchers examine how a cell distinguishes between damaged DNA and foreign viral DNA.

Genetic profiling after initial chemotherapy may help oncologists predict early prognosis.

Daratumumab causes the targeted killing of CD38-carrying tumor cells.

Vaccine primes immune cells to attack patient-specific tumor tissue.

The latest news in oncology treatment research.

Varubi prevents nausea and vomiting associated with vomit-inducing cancer chemotherapy.

Oncologists will now be able to measure progress in cancer treatments.

Elotuzumab is an immunostimulatory antibody combination therapy for patients who received one or more prior therapies.

Genentech official sheds light on the current cancer drug pipeline.

Dogs show promise in sniffing out melanoma, bladder, lung, breast, and ovarian cancers.

Researchers evaluate how PTEN protein regulates cell growth and how mutations can lead to cancer.

Researchers shed light on association between alcohol consumption and cancer.

Findings could lead to more effective treatments for diseases such as cancer and multiple sclerosis.

Ongoing clinical trial testing guadecitabine in Myelodysplastic syndromes and acute myelogenous leukemia.

Novel kinase cascade found to regulate cancer growth.

Sprycel label now includes 5-year first-line efficacy and safety data in adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.

New method may help personalize treatments for aggressive cancer.

Onsolis provides opioid tolerant patients with an alternative dosing option.